239 related articles for article (PubMed ID: 26022451)
1. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
Romano RC; Carter JM; Folpe AL
Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
Wu Y; Lai Y; Zhang M; Li Z
Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
[TBL] [Abstract][Full Text] [Related]
3. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins.
Miettinen M; Franssila K
Lab Invest; 1989 Dec; 61(6):623-8. PubMed ID: 2481151
[TBL] [Abstract][Full Text] [Related]
5. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
8. Malignant melanomas contain only the vimentin type of intermediate filaments.
Caselitz J; Jänner M; Breitbart E; Weber K; Osborn M
Virchows Arch A Pathol Anat Histopathol; 1983; 400(1):43-51. PubMed ID: 6190301
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.
Bahrami A; Gown AM; Baird GS; Hicks MJ; Folpe AL
Mod Pathol; 2008 Jul; 21(7):795-806. PubMed ID: 18487991
[TBL] [Abstract][Full Text] [Related]
10. Presence of fibroblast-type intermediate filaments (vimentin) and absence of neurofilaments in pigmented nevi and malignant melanomas.
Miettinen M; Lehto VP; Virtanen I
J Cutan Pathol; 1983 Jun; 10(3):188-92. PubMed ID: 6190849
[TBL] [Abstract][Full Text] [Related]
11. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics.
Koch MB; Shih IM; Weiss SW; Folpe AL
Am J Surg Pathol; 2001 Jan; 25(1):58-64. PubMed ID: 11145252
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma".
Torres-Mora J; Dry S; Li X; Binder S; Amin M; Folpe AL
Am J Surg Pathol; 2014 Jan; 38(1):94-105. PubMed ID: 24145644
[TBL] [Abstract][Full Text] [Related]
14. Intermediate filament expression in astrocytic neoplasms.
Cosgrove M; Fitzgibbons PL; Sherrod A; Chandrasoma PT; Martin SE
Am J Surg Pathol; 1989 Feb; 13(2):141-5. PubMed ID: 2464954
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
16. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas.
Sarlomo-Rikala M; Tsujimura T; Lendahl U; Miettinen M
APMIS; 2002 Jun; 110(6):499-507. PubMed ID: 12193211
[TBL] [Abstract][Full Text] [Related]
17. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
18. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
Eyden B; Pandit D; Banerjee SS
Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
[TBL] [Abstract][Full Text] [Related]
19. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.
Plaza JA; Suster D; Perez-Montiel D
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):421-5. PubMed ID: 18091385
[TBL] [Abstract][Full Text] [Related]
20. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
